Resonance Health

Resonance Health OCF/Debt

The Operating Cash Flow to Debt Ratio of Resonance Health (RHT.AX) as of Oct 6, 2026 is 75.61 %. In the previous year, Operating Cash Flow to Debt Ratio was 32.83 % — a change of 130.28% (higher).

OCF/Debt

75.61 %

YoY

130.28%

Last updated:

Operating Cash Flow to Debt Ratio of Resonance Health is 2026 75.61 % . Operating Cash Flow to Debt Ratio of Resonance Health was 2025 32.83 % . It decreases by 130.28% higher compared to the previous year.

The Resonance Health OCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF/Debt
Date
OCF/Debt
Jan 1, 2020
1,128.93 AUD
Jan 1, 2021
1,944.12 AUD
Jan 1, 2022
-542.51 AUD
Jan 1, 2023
-57.53 AUD
Jan 1, 2024
37.53 AUD
Jan 1, 2025
32.83 AUD
Jan 1, 2026
75.61 AUD
The Resonance Health OCF/Debt history
YEAROCF/DebtYoY
75.61 %+130.28%
32.83 %-12.52%
37.53 %-165.23%
-57.53 %-89.40%
-542.51 %-127.91%
1,944.12 %+72.21%
1,128.93 %—
Access this data via the Eulerpool API

Resonance Health Stock analysis

What does Resonance Health do? Resonance Health Ltd is an Australian company that operates in the medical technology industry. The company's business model is to offer groundbreaking solutions for the diagnosis and treatment of liver and iron diseases. As a pioneering company in the development of methods and technologies for quantifying liver and iron concentrations, Resonance Health continually sets new standards in the industry. The company was founded in 2000 by a team of biomedicine professionals from the University of Western Australia. Over the years, the company has gained a lot of experience and constantly evolved to keep up with the progress of medical technology. The goal is to provide patients with better treatment and improved quality of life. One division of the company is the development and manufacturing of diagnostic tools for quantifying liver and iron diseases such as hepatitis, fatty liver, or hemochromatosis. The quantification method used by Resonance Health is called FerriScan. This method is non-invasive and painless, using magnetic resonance imaging (MRI) to measure the concentration of iron in the tissue. This is particularly important as a change in iron content can indicate a progressing liver disease. In addition to the FerriScan diagnostic tool, Resonance Health also offers a software package for analyzing FerriScan results, which is used by physicians and clinicians to assess disease progression. Furthermore, the company also develops solutions in the field of hemochromatosis, a genetic disorder that can lead to increased iron levels in the body. Another division of Resonance Health is the provision of research and development services to further develop and improve FerriScan and other technologies. The company collaborates with other companies, scientific institutions, and universities to advance the current developments in liver and iron diagnostics. Resonance Health has a range of products that contribute to better diagnosis and treatment of liver and iron diseases. These include FerriScan, the FerriSmart software package for precise monitoring of iron and liver health, and Hepatica, a software supporting hospitals and clinics in the diagnosis of liver diseases. The company is an innovative leader in the industry, contributing to improving the quality of life for patients. The products and services of Resonance Health have helped doctors and clinicians to effectively treat and diagnose liver and iron diseases. Additionally, the company has established a strong scientific foundation and works closely with leading institutions to continuously develop innovative solutions. Resonance Health is a company with a rich history that continues to evolve to meet the demands of the medical technology industry. The company aims to continuously improve the diagnosis and treatment of liver and iron diseases and offer better solutions. Resonance Health is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Resonance Health stock

Operating Cash Flow to Debt Ratio of Resonance Health is 75.61 % in 2026.

Operating Cash Flow to Debt Ratio of Resonance Health changed from 32.83 % to 75.61 %, representing a 130.28% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow to Debt Ratio Resonance Health since 2006 – with annual values, charts, and detailed analysis.

OCF/Debt measures what percentage of total debt can be covered by annual operating cash flow. Higher ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow to Debt Ratio's Resonance Health with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — Resonance Health

All Key Metrics — Resonance Health